EMP16 – A NEW APPROACH TO TREAT OBESITY
and superior safety.
VISION
A world where obesity is no longer seen as a fault of the individual and where individualized treatment is available for everyone.
MISSION
To strive for universally accessible medications in the obesity medicine field, addressing the current lack of availability and serving as a game changer for individuals worldwide.
Partners
TRUST
Empros is a small company and highly dependent on external professionals. We carefully select these professionals, and once included they become “one of us”. We do not compartmentalize information and ideas, instead we trust that others use their skills and knowledge to help us move
TRANSPARENCY
Empros always strives to include everyone within the company. All team members should feel that they play an important role and see how their own activities and actions help the company forward. Empros sees this as a key component to foster intrinsic motivation, so that everyone is willing to put in that extra effort.
KNOWLEDGE-DRIVEN
Science is what Empros is built upon. We use previous knowledge to create something new, that we in turn share with both the scientific community and society as a whole. Here transparency comes back, all that we do must be reproducible and understandable for everyone
EMP16
The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes.
Clinical program
Learn more about our previous and ongoing studies.
ABOUT US
Empros Pharma AB was founded in late 2013 by senior researchers and entrepreneurs at Uppsala University together with Flerie Invest.
ABOUT US
Empros Pharma AB was founded in late 2013 by senior researchers and entrepreneurs at Uppsala University together with Flerie Invest.
This significant increase can be attributed to a complex interplay between genetic predisposition (influencing for example metabolism and appetite regulation) and environmental factors such as diet, stress, infection, pollution, and socioeconomic factors.